# INVESTMENT COMMITTEE -- RONDA 4 GATE REVIEW: FDS (FactSet Research Systems Inc.)

**Date:** 2026-02-14
**Analyst:** investment-committee (opus)
**Pipeline Stage:** R4 (Final Gate)
**Input Files:** thesis.md (R3 resolved), moat_assessment.md, risk_assessment.md, devils_advocate.md, valuation_report.md

---

## GATE 0: SECTOR VIEW EXISTS -- PASS

Sector view verified: `/home/angel/value_invest2/world/sectors/financial-data-analytics.md`
Last updated: 2026-02-13. Status: NEUTRAL-SELECTIVO. FDS is listed under "Analizadas" with FV $230, entry $180 (pre-R3 values).

---

## PASO 0.5: PRECEDENTES CONSULTADOS

**Most similar precedents from decisions_log.yaml:**

1. **ROP**: Tier B (QS 48 tool / 70 adjusted), 22% MoS at $300, sizing 4% (EUR 400), standing order. Outcome: pending. Relevance: Same sector proximity (B2B software/data), Tier B with narrow-wide moat, standing order discipline approach. WIDE moat justified lower MoS floor.

2. **MMC**: Tier B (QS 64 tool / 68 adjusted), 18.4% MoS at $155, sizing 2% (EUR 200, HALF POSITION due to Greensill binary). Outcome: pending. Relevance: Financial services sector, Tier B, standing order. 18.4% is the LOWEST MoS accepted for Tier B -- but only with exceptional WIDE moat + half position for binary risk.

3. **VLTO**: Tier B (QS 52 tool / 66 adjusted), 20% MoS at $80, sizing 4% (EUR 400), standing order. Outcome: pending. Relevance: Similar QS range to FDS (73 vs 66 adj), Tier B, standing order approach with price discipline.

**Pattern from precedents:**
- Tier B standing orders approved at 18.4-22% MoS
- All used price discipline (standing orders, not market buys)
- Standard sizing 4% (EUR 400) unless binary event (then HALF)
- All had wide moats or narrow-leaning-wide

**FDS deviation analysis:** FDS has a NARROW moat (not WIDE), which is weaker than ROP/MMC/ACGL. This argues for MoS at or above the upper end of the Tier B range (20-25%), not the lower end (18-20%).

---

## GATE 1: QUALITY SCORE -- PASS

```
[X] Quality Score calculated: 73/100 (quality_scorer.py confirmed)
[X] Tier assigned: B (Quality Value)
[X] Tier D check: NOT Tier D -- proceed
[X] QS verified with tool
```

**QS Tool: 73/100 (Tier B)**

| Category | Score | Max | Notes |
|----------|-------|-----|-------|
| Financial | 35 | 40 | ROIC +11.1pp (12/15), FCF 27% (10/10), ND/EBITDA 1.4x (8/10), FCF 4/4yr (5/5) |
| Growth | 16 | 25 | Rev CAGR 8% (5/10), EPS CAGR 14.7% (8/10), GM stable (3/5) |
| Moat | 17 | 25 | GM premium +22.7pp (10/10), Market Position 0/8 (tool default), ROIC persistence 7/7 |
| CapAlloc | 5 | 10 | Dividends (5/5), Insider 0.4% (0/5) |

**QS Adjusted: 73/100 -- No adjustment warranted.**

Reasoning: The tool assigns 0/8 for market position (known default issue). FDS is #2 in financial data with 22% share, warranting 5/8 points. However, this would push QS to 78 (Tier A), and the adversarial standard (Session 52) prohibits inflating scores upward without strong justification. The business characteristics (8% revenue CAGR, 0.4% insider ownership, NARROW moat with active threats) are firmly Tier B, not Tier A. QS 73 is appropriate.

**Does FDS qualify as Tier A (Principio 9)?** NO. Despite near-Tier-A financial quality (35/40), the growth deceleration to 5-6% organic, NARROW moat classification, and active AI disruption threats make this a solid Tier B, not a quality compounder.

---

## GATE 2: BUSINESS UNDERSTANDING -- PASS

```
[X] Business Analysis Framework completed
[X] Can explain in 2 minutes
[X] Know WHY it is cheap + counter-thesis
[X] Value trap checklist: 0.5/10 SI
[X] Informational advantage identified
```

**2-minute explanation:**
FactSet is the #2 financial data platform (22% share, behind Bloomberg at 33%). It aggregates data from 200+ sources and layers proprietary analytics (PA/SPAR tools) on top. 100% subscription revenue ($2.4B ASV), 95%+ dollar retention, $617M FCF. The stock has fallen 57% from ATH because: (1) margins are compressing as FDS invests in cloud migration (Open:FactSet) and AI (Mercury), (2) organic ASV growth decelerated from 11% historical to 5.9%, (3) AI fears threaten the analytics layer and buy-side seat count. The market prices FDS at P/E 13x -- the lowest in its history outside 2008-2009.

My counter-thesis: margin compression is investment-driven (temporary, should normalize FY2028), the 95%+ retention proves product stickiness, and P/E 13x for this quality level is historically anomalous. But: AI disruption, revenue-per-user decline, and competitive squeeze from Bloomberg (10x R&D budget) are real correlated risks.

**Value trap score: 0.5/10** -- Only partial concern on AI disruption. NOT a classic value trap (profitable, growing, strong cash generation).

**Informational advantage:** Longer time horizon (market is pricing in permanent margin compression that is likely temporary) + market over-reacting to multiple headwinds simultaneously.

---

## GATE 3: PROJECTIONS -- PASS

```
[X] Revenue growth derived (TAM/share/pricing): 6% base
[X] WACC calculated (Rf + Beta*ERP): 9.0% (7.4% calculated + 1.6pp premium)
[X] Terminal growth justified: 2.5% (below GDP, reflecting mature financial data)
[X] Scenarios Bear/Base/Bull documented
```

| Scenario | Revenue Growth | Adj Op Margin | WACC | Terminal | FV |
|----------|---------------|---------------|------|----------|----|
| Bear (25%) | 4% | 33% | 10.5% | 2.0% | $170 |
| Base (50%) | 6% | 36% | 9.0% | 2.5% | $210 |
| Bull (25%) | 8% | 38% | 8.0% | 3.0% | $290 |

Revenue growth derivation: TAM +4% + delta share +0.5% + pricing +2% = ~6.5%, rounded down to 6%.

**R3 Resolution applied:** FV reduced from $225 to $210 to incorporate correlated risk discount for AI+competition+headcount triple threat, and CEO transition from Snow to Viswanathan (Sep 2025). This 7% haircut is appropriate and documented.

---

## GATE 4: VALUATION MULTI-METHOD -- PASS

```
[X] Methods appropriate for Tier B:
    - DCF with SBC adjustment (Primary, 60%)
    - EV/EBIT Normalized (Secondary, 40%)

[X] Method 1: DCF (SBC-adjusted) -> FV $244 (pre-R3)
[X] Method 2: EV/EBIT (15x, SBC-adjusted) -> FV $218 (pre-R3)
[X] Weighted Average: $233 -> Rounded to $225 (conservative)
[X] R3 Correlated Risk Discount: -7% -> $210
[X] Divergence: 12% (ACCEPTABLE, <30%)
```

**Valuation specialist and thesis converge on $210 post-R3 adjustment.** Two methods agree within 12% (DCF $244 vs EV/EBIT $218, pre-adjustment). Convergence increases confidence despite HIGH DCF sensitivity (87% FV spread, 75% TV as % of EV).

**Sensitivity concern:** At WACC 10.5% / Growth 3% (stressed), SBC-adjusted FV = $166 -- 19% below current price. This downside exists and is documented.

**Cross-check (Owner Earnings Yield):** OEY 6.9% + Expected Growth 5.5% = 12.4% vs WACC 9.0%. Spread +3.4pp -- positive, confirms value creation at current price.

**Reverse DCF:** Market implies ~3% growth at current price ($204). My base case is 6%. Either market is right (AI/competition halves growth) or this is mispriced. The 0-1 Buy ratings from 19 analysts suggest the market is pricing in a genuinely negative view.

---

## GATE 5: MARGIN OF SAFETY (Reasoned v4.0) -- PASS (at entry $170, FAIL at current $205)

```
[X] Tier: B
[X] MoS Actual vs Base ($210): +2.5% at current $205 -- INSUFFICIENT
[X] MoS at Entry $170 vs Base ($210): +19% -- ADEQUATE
[X] MoS at Entry $170 vs Bear ($170): 0% -- BREAK-EVEN with bear case
```

**Reasoning:**

At current price $205.79 (EUR 173.34):
- MoS vs R3 FV $210: only +2.0% -- FAR below Tier B precedent range of 18-25%
- MoS vs Bear $170: NEGATIVE (-17.1%) -- price is well above bear case
- This is NOT a buy at current prices. The MoS is grossly insufficient.

At proposed entry $170:
- MoS vs R3 FV $210: +19.0%
- MoS vs Bear $170: 0% -- exactly at bear case
- MoS vs Expected Value ($228): +25.4%

**Precedent comparison:**
- ROP: 22% MoS at standing order, WIDE moat -> FDS at 19% with NARROW moat is tighter
- MMC: 18.4% MoS, WIDE moat + HALF position -> FDS NARROW moat without half position constraint
- VLTO: 20% MoS, NARROW-leaning-WIDE moat -> Most comparable

**Am I deviating from precedents?** YES -- 19% MoS for NARROW moat is at the low end. But:
1. FDS has 95%+ ASV retention (among the highest in our universe)
2. ROIC spread +11.1pp is strong and persistent (4/4 years data, 10yr avg 25.1% per Gurufocus)
3. FCF margin 27% provides real earnings floor
4. The R3 FV of $210 already incorporates a 7% correlated risk discount

However, the bear case MoS of 0% at $170 is concerning. If all three correlated risks materialize, we break even at best. The risk-identifier recommended $160-170; the devil's advocate recommended $165-170. The lower bound ($165) would provide 4.8% MoS vs bear and 21.4% vs base -- better aligned with precedents.

**Committee decision on entry:** $170 is acceptable but $165 would be more prudent. I accept $170 as the entry with a CONDITIONAL note: if FDS reaches $170 but Q2 FY2026 earnings (March 2026) show ASV growth <5% or margins below guidance, do NOT execute -- wait for further decline.

---

## GATE 6: MACRO CONTEXT -- PASS

```
[X] World view reviewed (date: 2026-02-14)
[X] Economic cycle: Mid-cycle US
[X] Company-cycle fit evaluated
[X] Megatrends: AI [-/+], Demographics [neutral], Desglobalization [+]
```

**Macro context:**
- US mid-cycle, CPI moderating (2.4% Jan 2026), Fed on hold. Neutral for financial data demand.
- Financial data is defensive/secular -- not particularly sensitive to current macro uncertainties.
- AI megatrend is DUAL: threat (disrupts analytics layer, reduces seats) AND opportunity (Mercury AI, new product revenue). Net assessment: slight negative for FDS specifically.
- USD weakness (DXY 96.8) is mildly negative for FDS (65% Americas revenue, rest in local currency).

**Sector view:** NEUTRAL-SELECTIVO. The sector has exceptional moats in sub-segments (ratings, indices) but FDS sits in the more vulnerable "terminals/analytics" sub-segment where AI disruption is most relevant.

---

## GATE 7: PORTFOLIO FIT (Reasoned v4.0) -- PASS

```
[X] Price verified: $205.79 / EUR 173.34 (2026-02-14)
[X] Sizing proposed: 4% (EUR 400) -- standard Tier B
```

**constraint_checker.py output (CHECK FDS 400):**
- Position post-purchase: 4.0% -- Coherent with Tier B precedents (ROP 4%, VLTO 4%, ACGL 4%)
- Sector Financial Services: 18.5% post-purchase -- This is elevated. However, FDS (financial data) is not correlated with ALL/GL (insurance). Different business drivers. Acceptable.
- Geography US: 18.5% post-purchase -- Well within prudent range. Currently UK-heavy (4 positions), so adding US diversifies geography.
- Cash post-purchase: EUR 5,352 (53.0%) -- Ample cash. No constraint.
- 50% drawdown impact: -2.0% portfolio -- Acceptable for medium conviction Tier B.

**Correlation with existing positions:**
- ALL, GL are insurance -- different sub-sector. LOW correlation.
- ADBE is tech/software -- different customer base. LOW correlation.
- MONY.L is UK comparison platform -- different market. LOW correlation.
- No existing position in financial data/analytics. FDS adds sector diversification.

**Precedent sizing: ROP 4%, VLTO 4%, ACGL 4% (all Tier B standing orders).** FDS at 4% is consistent.

**Am I deviating?** NO. Standard Tier B sizing at 4% with standing order discipline.

---

## GATE 8: SECTOR UNDERSTANDING -- PASS

```
[X] Sector view exists: world/sectors/financial-data-analytics.md
[X] Sector view reviewed (date: 2026-02-13)
[X] TAM and trends understood
[X] Disruption risks known
[X] Sector position: NEUTRAL-SELECTIVO
```

Key sector observations:
- Financial data TAM ~$50B global, growing 8-10% CAGR
- FDS sits in the "terminals/analytics" sub-segment, NOT in the moat-rich "ratings/indices" sub-segments
- Peers MSCI (82% GM), VRSK (73% GM), SPGI (70% GM) have structurally higher margins than FDS (53% GM) because they CREATE proprietary data while FDS AGGREGATES
- VRSK is in R3 pipeline (FV $185, entry $150) -- VRSK has better moat (proprietary data creation) and higher margins. If VRSK reaches entry, it is likely superior to FDS in same sector.
- MORN R4 approved, entry $135, QS 78 adj (Tier A) -- also in sector, potentially superior

**Sector comparison implication:** FDS is the WEAKEST of the three financial data candidates (FDS, VRSK, MORN) based on moat quality. However, FDS is closest to entry (12% above $170 vs VRSK 15%+ above $150 and MORN ~18% above $135). If we can only deploy in one, VRSK or MORN are preferable but less actionable.

---

## GATE 9: SELF-CRITIQUE -- PASS

```
[X] Unvalidated assumptions listed
[X] Biases recognized:
    [X] Popularity bias: FDS is a well-known financial data name -- VALIDATED with quality_scorer.py data
    [X] Confirmation bias: The 57% decline creates "fallen angel" narrative -- tempered by 0/19 Buy ratings
    [X] Recency bias: Recent price decline creates sense of opportunity -- but decline may be rational
[X] Kill conditions defined
[X] What would change my mind
```

**Unvalidated assumptions:**
1. Margin normalization FY2028 -- management has NOT committed to a timeline. Could be FY2029-2030.
2. AI product monetization (Mercury) -- very early, no revenue data. Could be immaterial.
3. SBC data: $61M vs MacroTrends $152M discrepancy unresolved. If true SBC is $150M, FV drops ~$15-20.
4. New CEO Viswanathan's effectiveness -- only 5 months in role. Unknown.

**What would change my mind (making me MORE bearish):**
- Q2 FY2026 organic ASV growth <4% (structural deceleration confirmed)
- Revenue per user declining >5% YoY (unit economics broken)
- Major buy-side client publicly replaces FDS with AI-native tool
- CUSIP antitrust adverse ruling
- Adj operating margin falls below 33% (below guidance low end)

**What would change my mind (making me MORE bullish):**
- ASV growth reaccelerates to 7%+ (AI fears overblown)
- Mercury AI drives $50M+ net new ASV in FY2026
- Margin guidance raised (investment phase shorter than feared)

---

## GATE 10: COUNTER-ANALYSIS & INDEPENDENT ASSESSMENTS -- CONDITIONAL PASS

```
[X] Counter-analysis (devils_advocate.md) exists: YES
[X] Verdict: MODERATE COUNTER (10/20 conviction)
[X] Challenges HIGH/CRITICAL: 1 CRITICAL + 3 HIGH
[X] Moat assessment exists: YES (NARROW classification)
[X] Risk assessment exists: YES (MEDIUM-HIGH)
[X] Valuation report exists: YES (FV $225 pre-R3, $210 post-R3)
```

### CRITICAL Challenge Resolution: CEO Transition Missed

The devil's advocate identified that Philip Snow retired as CEO in September 2025, replaced by Sanoke Viswanathan (ex-JPMorgan). The original thesis had KC#6 referencing Snow's departure as a kill condition -- which was ALREADY TRIGGERED.

**Resolution:** The R3 resolution (thesis header line 5) explicitly addresses this: "CEO Snow retired Sep 2025 (thesis missed), replaced by Viswanathan (ex-JPMorgan). KC#6 replaced." The FV was reduced $225 to $210 partially because of this CEO transition uncertainty.

**Committee assessment:** Viswanathan has JPMorgan Consumer & Wealth background, which is relevant (wealth is FDS's fastest growing segment at 10%). But he is an outsider with zero FactSet experience, taking over during a critical cloud migration and AI pivot. This adds execution risk. The 7% FV haircut in R3 is adequate to cover this risk. KC#6 is now replaced with: "Viswanathan departure within 18 months OR strategic direction reversal."

### HIGH Challenge #1: Revenue-Per-User Structural Decline

Users +9.7% but ASV +5.9% -- revenue per user declining 3.5% YoY. Wealth expansion at lower ARPU dilutes mix.

**Resolution:** This is acknowledged in the R3 thesis and partially priced into the 6% growth assumption (not 8%+). However, if ARPU decline continues at -3%/yr, organic growth converges to 3-4% (bear case). The HARD GATE for Q2 FY2026 earnings will test this. Kill condition KC#7 added for revenue-per-user decline >5% YoY for 2 consecutive quarters.

### HIGH Challenge #2: Data Aggregator Vulnerability

FDS gross margin 53% vs MSCI 82%, VRSK 73%. Structurally lower margins because FDS aggregates data, not creates it.

**Resolution:** This is a STRUCTURAL issue, not fixable. It means FDS will NEVER command the margins of MSCI/VRSK. However, it is already reflected in the EV/EBIT multiple selection (15x vs 27x sector median) and in the QS (73 vs what MSCI/VRSK would score). The valuation does not assume margin parity with data creators. ACCEPTED AS STRUCTURAL RISK, priced into FV.

### HIGH Challenge #3: Correlated Triple Threat (AI + Competition + Headcount)

Three HIGH risks are correlated: AI disrupts analytics, Bloomberg/SPGI outspend on tech, buy-side headcount reduction shrinks seats.

**Resolution:** R3 applied a 7% correlated risk discount ($225 to $210). The entry price of $170 provides additional cushion. However, if all three materialize simultaneously, the deep bear case is $130-140 (10-15% probability). At $170 entry, this represents -18% to -24% downside.

**Committee assessment:** The correlated risk is real but not unpriced. P/E 13x (at current prices) already embeds massive pessimism. At $170, P/E would be ~11x -- historical trough levels (only seen in 2008-2009). The 19% MoS vs base and 0% vs bear is tight but acceptable given:
(a) 95%+ retention provides earnings floor
(b) FCF of $617M ($556M SBC-adjusted) supports the stock even if growth stalls
(c) $1B buyback authorization provides incremental support

### Moat Assessment Alignment

Moat assessment: NARROW. Thesis: NARROW-WIDE. R3 resolution: accepted NARROW.

**Committee assessment:** NARROW is the correct classification. Only ONE moat source (switching costs) is strong. The analytics layer (secondary moat source) is actively threatened by AI. This is consistent with the lower end of Tier B treatment (not Tier A).

### Risk Assessment Alignment

Risk score: MEDIUM-HIGH. 3 HIGH risks identified, all correlated.

**Committee assessment:** MEDIUM-HIGH is appropriate. The entry price of $170 compensates for this elevated risk profile. However, the HARD GATE for Q2 FY2026 earnings is essential -- we need to see that the risks are not materializing faster than expected.

### Valuation Report Alignment

Valuation specialist FV: $225 (pre-R3). R3 adjusted: $210. Divergence: 0% (thesis and valuation aligned).

**Committee assessment:** Methods converge well. The $210 FV is conservative and defensible.

### Unresolved Conflicts

1. **SBC discrepancy ($61M vs $152M from MacroTrends)**: The 10-K confirms $61M. MacroTrends may include different items. For now, $61M is used. FLAG: if true SBC is $150M+, FV drops to ~$190-195.

2. **VRSK as superior alternative**: VRSK (R3 complete, FV $185, entry $150) has better moat and margins. If both reach entry simultaneously, VRSK is preferred. This is documented, not a conflict.

3. **19 analysts, 0-1 Buy ratings**: The committee cannot dismiss this. Our edge must be specific: longer time horizon + belief margin compression is temporary + 95% retention provides floor. This is a valid but NARROW edge.

---

## KILL CONDITIONS (FINAL, POST-R3)

1. **KC#1:** Organic ASV growth falls below 3% for 2 consecutive quarters
2. **KC#2:** Adjusted operating margin falls below 30%
3. **KC#3:** ASV retention drops below 92%
4. **KC#4:** AI-driven seat count reduction >10% at major clients (SaaSpocalypse)
5. **KC#5:** Management announces major acquisition >$3B
6. **KC#6 (REPLACED):** Viswanathan departure within 18 months OR strategic direction reversal (e.g., abandoning cloud migration, major pivot)
7. **KC#7 (NEW):** Revenue per user declines >5% YoY for 2 consecutive quarters

---

## VERDICT: WATCHLIST -- Standing Order at $170

### Gate Summary

| Gate | Status | Key Issue |
|------|--------|-----------|
| 0. Sector View | PASS | financial-data-analytics.md exists |
| 1. Quality Score | PASS | QS 73, Tier B, no adjustment |
| 2. Business Understanding | PASS | Can explain, counter-thesis documented, VT 0.5/10 |
| 3. Projections | PASS | Revenue 6% derived, WACC 9.0% derived, scenarios complete |
| 4. Valuation | PASS | DCF + EV/EBIT converge, $210 post-R3 |
| 5. Margin of Safety | PASS at $170 | 19% MoS vs $210, tight but acceptable for Tier B |
| 6. Macro Context | PASS | Mid-cycle neutral, financial data defensive |
| 7. Portfolio Fit | PASS | 4% sizing, low correlation, US geo diversification |
| 8. Sector Understanding | PASS | Sector view complete, FDS weakest of 3 candidates |
| 9. Self-Critique | PASS | Biases documented, unknowns listed |
| 10. Counter-Analysis | CONDITIONAL PASS | 1 CRITICAL (resolved), 3 HIGH (mitigated via R3 FV cut + entry price) |

### RECOMMENDATION

```
RECOMMENDATION: WATCHLIST with Standing Order at $170

Quality Score: 73/100 -> Tier B (Quality Value)
Fair Value (R3 Resolved): $210
Entry Price: $170 (MoS 19% vs base, 0% vs bear)
Sizing: EUR 400 (4% of portfolio)
Category: Quality Value (Defensive Subscription)
Moat: NARROW (switching costs primary, analytics layer weakening)
Risk Score: MEDIUM-HIGH (3 correlated HIGH risks)
Risk Principal: AI + Competition + Buy-side headcount triple threat (correlated)

Kill Conditions: 7 defined (see above)

HARD GATE: Q2 FY2026 earnings (March 2026)
- Before executing standing order, verify:
  (a) Organic ASV growth >= 5% (not decelerating further)
  (b) Revenue per user trend stabilizing (not accelerating decline)
  (c) Adjusted operating margin within guidance (34-35.5%)
  (d) Viswanathan strategic commentary (credible AI/cloud plan)
- If ANY of (a)-(d) fail: REVISE entry downward to $155-160 or DEFER

PRE-EXECUTION CONDITION: Q2 FY2026 earnings must validate margin and growth trajectory.

Precedent Sizing: ROP 4% ($300 standing order), VLTO 4% ($80), ACGL 4% ($88)
Deviation from Precedents: 19% MoS is at low end for NARROW moat (vs 20-22% for WIDE moat peers). Justified by:
  - 95%+ retention (exceptional stickiness)
  - ROIC +11pp spread (strong value creation)
  - R3 FV already haircut 7% for correlated risks
  - Hard gate provides additional protection

SECTOR NOTE: If VRSK reaches $150 entry before FDS reaches $170, VRSK is preferred
(better moat, higher margins, proprietary data creation vs aggregation).
```

### Standing Order Parameters

```
Ticker: FDS
Entry Price: $170.00
Size: EUR 400 (~2.3 shares at $170)
Valid Until: Q2 FY2026 earnings (March 2026)
Hard Gate: PRE-EXECUTION -- verify Q2 earnings before executing
FV: $210 (R3 resolved)
MoS at Entry: 19%
Kill Conditions: 7 defined
```

### Why NOT APPROVED for immediate buy at current price $205?

1. MoS at $205 is only 2.5% vs FV $210 -- FAR below the 18-25% Tier B range
2. MoS vs bear ($170) is NEGATIVE at current price
3. 0-1 of 19 analysts rate Buy -- extraordinary consensus against
4. No near-term catalyst (Q2 earnings March 2026 is next data point)
5. NARROW moat with 3 correlated HIGH risks demands adequate compensation

---

## META-REFLECTION

### Dudas sobre esta decision

- **The 0% MoS vs bear at $170 entry is the biggest concern.** If the bear case materializes, we break even at best. Precedents (ROP $300 has bear $245, providing 22% cushion; VLTO $80 has bear $75, only -6.3% cushion) show this is not unprecedented (VLTO's bear case was also tight to entry) but it is not comfortable. The hard gate for Q2 earnings is essential.

- **19/19 analysts do not recommend buying.** When I am the lone contrarian, the burden of proof is on me. My edge is "longer time horizon + temporary margin compression" -- which is valid but narrow. If I am wrong and the market is right (AI permanently impairs the business model), the loss could be 15-25% even from $170.

- **The SBC discrepancy remains unresolved.** If the true economic cost of equity compensation is $150M (not $61M), the FV drops to $190-195 and the $170 entry becomes more reasonable but the thesis needs revision.

### Debilidades del analisis recibido

- **R1 thesis missed the CEO transition entirely.** This was caught by the devil's advocate and resolved in R3, but it reveals a gap in the fundamental analyst's data currency. CEO changes should be verified as part of standard R1 procedure.

- **Revenue-per-user trend insufficiently analyzed.** The thesis acknowledges it but treats it as a feature ("growing total ASV"). The counter-analysis correctly identifies this as potentially structural. Need deeper analysis of whether institutional ARPU is holding.

- **CUSIP litigation risk not quantified in FV.** The $175M/year revenue from CUSIP at high margins is at risk. An adverse ruling could reduce FV by $15-25. This should be modeled as a separate scenario rather than lumped into the general bear case.

### Sugerencias de mejora

- **Add corporate governance verification to R1 checklist.** CEO changes, CFO departures, board reshuffles should be standard verification items for the fundamental analyst.

- **Sector view needs updating.** The sector view still shows FDS at FV $230 (pre-R3). Should be updated to $210 and entry $170.

- **Create explicit "within-sector ranking" for sectors with multiple candidates.** Financial Data & Analytics has FDS, VRSK, and MORN. A ranking by moat quality / valuation attractiveness would help prioritize.

### Preguntas para Orchestrator

1. Should the standing order for FDS be set now at $170, or should we wait for Q2 FY2026 earnings (March 2026) to validate before setting any order? The HARD GATE makes the order conditional, but there is a risk that FDS drops to $170 before March and the hard gate has not been satisfied.

2. Given that VRSK (better moat, higher margins) is also in the sector at R3 complete, should we explicitly prioritize VRSK over FDS and defer the FDS standing order until VRSK is addressed?

3. The SBC discrepancy ($61M vs $152M) could materially affect the valuation. Should we task quant-tools-dev to pull the 10-K SBC detail via SEC EDGAR to resolve this before committing the standing order?

---

**Committee Decision Date:** 2026-02-14
**Committee:** investment-committee (opus)
**Pipeline Stage:** R4 COMPLETE
**Verdict:** WATCHLIST -- Standing Order $170 with Q2 earnings hard gate
**Output file:** thesis/research/FDS/committee_decision.md (to be created when plan mode exits)
